Australian panel report on TGA's transparency postponed
This article was originally published in SRA
An Australian panel that is reviewing the transparency around Therapeutic Goods Administration's regulatory decision making process has been given an extension until 30 June to present its final report to the government1.
You may also be interested in...
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.